$IDXG News

Last published 3mo ago

3mo agoIDXGInterpace Biosciences Announces Second Quarter 2026 Financial and Business ResultsGlobeNewswireQ2 Revenue of $9.1 millionQ2 Income from Continuing Operations of $0.3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36.1
6mo agoIDXGInterpace Biosciences Announces First Quarter 2026 Financial and Business ResultsGlobeNewswireQ1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year increase of 10%Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE
7mo agoIDXGInterpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business ResultsGlobeNewswireQ4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid
12mo agoIDXGInterpace Biosciences Announces Third Quarter 2025 Financial and Business ResultsGlobeNewswire●Q3 Revenue of $8.8 million ●Q3 Cash Collections of $10.0 million ●Q3 Thyroid test volume up 12% year-over-year to record levels ●Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ,
1y agoIDXGInterpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual MeetingGlobeNewswireHighlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic
1y agoIDXGInterpace Biosciences Announces Second Quarter 2025 Financial and Business ResultsGlobeNewswire●Q2 Revenue of $9.2 million ●Q2 Cash Collections of $10.8 million ●Q2 Thyroid test volume up 16% year-over-year to record levels ●Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug.
1y agoIDXGInterpace Biosciences Announces First Quarter 2025 Financial and Business ResultsGlobeNewswire●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1
1y agoIDXGEffective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer RiskGlobeNewswireInterpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the
1y agoIDXGInterpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business ResultsGlobeNewswire●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc.
1y agoIDXGPancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring PlanGlobeNewswirePARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced notification that the Centers for
1y agoIDXGEffective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer RiskGlobeNewswirePARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today responded to the final Local Coverage
2y agoIDXGInterpace Biosciences Announces Record Third Quarter 2024 Financial and Business ResultsGlobeNewswire●Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ●Q3 Test volume up 26% year over year to record levels ●Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ●Q3 Volume, Revenue,
2y agoIDXGInterpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to NasdaqGlobeNewswirePARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that its Series B Preferred Stock investors, Ampersand Capital Partners and 1315
2y agoIDXGInterpace Biosciences Announces Record Second Quarter 2024 Financial and Business ResultsGlobeNewswire●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ●Q2 Volume, Revenue, and
2y agoIDXGInterpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic CystsGlobeNewswirePARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today responded to the undefined extension granted
2y agoIDXGInterpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 AbstractGlobeNewswirePARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences® (OTCQX:IDXG), is proud to announce that new data demonstrating the application of advanced
2y agoIDXGInterpace Biosciences Announces First Quarter 2024 Financial and Business ResultsGlobeNewswire●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the
2y agoIDXGInterpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business ResultsGlobeNewswire●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and 119% increase
3y agoIDXGInterpace Biosciences Announces Record Third Quarter 2023 Financial and Business ResultsGlobeNewswire●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection
3y agoIDXGInterpace Biosciences Announces Record Second Quarter 2023 Financial and Business ResultsGlobeNewswire●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year driven by additional
3y agoIDXGInterpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® ReimbursementGlobeNewswireQ2 Revenue of $11 million; a 49.1% increase year-over-year and 12.2% better than Q1; highest quarter in history1st Half Revenue $20.9 million; 36.1% improvement over 1st Half 2022Q2 Test volume up 15.2% year-over-year to
3y agoIDXGInterpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023GlobeNewswirePARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final
3y agoIDXGInterpace Biosciences Announces Record First Quarter 2023 Financial and Business ResultsGlobeNewswire●Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ●Q1 Test volume up nearly 20% year over year to record levels ●Q1 41.9 million covered lives added, resulting from 8 new or updated
3y agoIDXGInterpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business ResultsGlobeNewswire●Q4 Revenue of $8.3 million ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company")
3y agoIDXGInterpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going ConcernGlobeNewswireQ3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Interpace
4y agoIDXGInterpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual MeetingGlobeNewswirePARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic
4y agoIDXGInterpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly ImprovedGlobeNewswirePARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for im
4y agoIDXGInterpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.GlobeNewswireInterpace Transitions to focused Molecular Diagnostics Business Disposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OT
4y agoIDXGInterpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly ImprovedGlobeNewswire●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding (DSO) decreased by 15% PARSIPPANY, NJ, Aug
4y agoIDXG TWSTInterpace Biosciences Announces First Quarter 2022 Financial and Business ResultsGlobeNewswire●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace
4y agoIDXG TWSTMiroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist BioscienceGlobeNewswirePARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX:IDXG) ("Interpace" or the "Company"), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary t
4y agoIDXGInterpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business ResultsGlobeNewswire●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ●Full year Cash Collections improved by 31% to $4
4y agoIDXGInterpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid TestsGlobeNewswirePARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX:IDXG) ("Interpace" or the "Company"), a leader in enabling personalized medicine, announced today that the National Correct Coding Initiative (NCCI) program issued a r
4y agoIDXGInterpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid TestsGlobeNewswirePARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX:IDXG) ("Interpace" or the "Company") a leader in enabling personalized medicine, announced today that it was terminating its previously announced rights offering and t
4y agoIDXGInterpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New DirectorGlobeNewswirePARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX:IDXG) ("Interpace") a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of
4y agoIDXGInterpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights OfferingGlobeNewswirePARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. Under the
4y agoIDXGInterpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights OfferingGlobeNewswireProceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that it has set the re
5y agoIDXGInterpace Biosciences Announces Third Quarter 2021 Financial and Business ResultsGlobeNewswire●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Cred
5y agoIDXGInterpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity LoansGlobeNewswirePARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that it, along with its subsidiaries, has entered into a new $8 million term loan with BroadOak Fund V, L.P. ("Bro
5y agoIDXGInterpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related ConditionsGlobeNewswirePARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for imp
5y agoIDXGInterpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid NeoplasmsGlobeNewswirePARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for imp
5y agoIDXGInterpace Biosciences Announces New $7.5 Million Credit Facility with Comerica BankGlobeNewswirePARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica
5y agoIDXGInterpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology ServicesGlobeNewswireParsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) announced today that it will offer a new capability in providing Digital Spatial Profil
5y agoIDXGInterpace Biosciences Announces First Quarter 2021 Financial and Business ResultsGlobeNewswire● Q1 Revenue of $9.8 Million is Company's Highest as Combined Molecular Diagnostics and Pharma Services Business ● Q2 Revenue Expected to Exceed $11 million ● On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Moving Up Target For E
5y agoIDXGInterpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®GlobeNewswireParsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) announced today that eviCore Healthcare ("eviCore"), a wholly owned subsidiary of Cigna, has updated their laboratory management gu
5y agoIDXGInterpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder ValueGlobeNewswireParsippany, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today issued the following statement. Interpace continues to make progress executing its growth strategy and the Company
5y agoIDXGInterpace Biosciences Raises Full Year 2021 Revenue GuidanceGlobeNewswireParsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021. "We saw increased and
5y agoIDXGInterpace Biosciences Announces Acceptance for Trading on the OTCQXGlobeNewswirePARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...
5y agoIDXGInterpace Biosciences Announces Impending Delisting from NasdaqGlobeNewswirePARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on...
5y agoIDXGInterpace Biosciences Announces Path Forward in Letter to ShareholdersGlobeNewswirePARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to...